## Confirmatory Testing for ESBL-Producing E. coli ### Clinical Context ESBL-producing E. coli is a major cause of community-acquired and nosocomial urinary tract infections in India. ESBL-producing organisms are resistant to third-generation cephalosporins (ceftriaxone, cefotaxime) but remain susceptible to beta-lactam/beta-lactamase inhibitor combinations and carbapenems. Accurate identification is critical for appropriate therapy. ### Why Double-Disk Synergy Test (DDST) is Correct **Key Point:** The **double-disk synergy test (DDST)** is the **gold standard confirmatory test** for ESBL production. It demonstrates the hallmark feature of ESBLs: inhibition of the enzyme by clavulanic acid. **High-Yield:** DDST Protocol: 1. Place a cephalosporin disk (ceftriaxone or cefotaxime, 30 µg) on the agar plate 2. Place an amoxicillin-clavulanic acid disk (20/10 µg) 15–30 mm away 3. **Positive result:** Enhanced zone of inhibition around the cephalosporin disk ("keyhole" or "halo" effect) due to clavulanic acid inactivating the ESBL enzyme 4. **Interpretation:** Confirms ESBL production **Mnemonic:** **DDST = Dual Disk Synergy Test** — two disks placed together show synergy (enhanced inhibition) when ESBL is present. ### Why DDST is Superior to Other Tests | Test | Principle | Sensitivity | Specificity | Limitation | |---|---|---|---|---| | **DDST (cephalosporin + clavulanic acid)** | **Clavulanic acid inhibits ESBL** | **95–100%** | **95–100%** | **Gold standard** | | Cephalosporin disk alone | Zone diameter cutoff | 85–90% | 80–85% | Cannot distinguish ESBL from intrinsic resistance; false negatives with inoculum variation | | Nitrocefin test | Non-specific beta-lactamase detection | 90% | 70% | Detects all beta-lactamases (AmpC, carbapenemase), not ESBL-specific | | Carbapenem disk | Resistance pattern | N/A | N/A | Used to rule out carbapenemase; not confirmatory for ESBL | **Clinical Pearl:** ESBL-producing organisms are inhibited by clavulanic acid (a beta-lactamase inhibitor), whereas AmpC-producing and carbapenemase-producing organisms are **not** inhibited. DDST exploits this difference. ### Why Other Options Are Suboptimal **Cephalosporin Disk Alone (Option 0):** While a cephalosporin disk with zone diameter ≤22 mm (for ceftriaxone) or ≤27 mm (for cefotaxime) suggests ESBL, this is a **screening test, not confirmatory**. Zone diameters can vary with inoculum density and medium pH, leading to false negatives. Confirmation requires the synergy effect with clavulanic acid. **Nitrocefin Test (Option 2):** Nitrocefin is a chromogenic cephalosporin that detects **any beta-lactamase** (ESBL, AmpC, carbapenemase). It is not specific for ESBL. A positive nitrocefin test does not confirm ESBL — the organism could produce AmpC or other non-ESBL beta-lactamases. **Carbapenem Disk (Option 3):** Carbapenems are used to **rule out carbapenemase** (which would confer resistance to carbapenems). ESBL-producing organisms remain susceptible to carbapenems. A carbapenem disk is not confirmatory for ESBL; it is used for a different purpose (detecting resistance to last-line therapy). ### Clinical Management Implication Once ESBL is confirmed by DDST, the organism is reported as resistant to cephalosporins but susceptible to: - Beta-lactam/beta-lactamase inhibitor combinations (amoxicillin-clavulanic acid, piperacillin-tazobactam) - Carbapenems (meropenem, imipenem) — reserved for severe infections - Fluoroquinolones (if susceptible) [cite:Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing; Koneman's Color Atlas and Textbook of Diagnostic Microbiology 7e]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.